PRMT1 is required for the generation of MHC-associated microglia and remyelination in the central nervous system.
Jeesan LeeOscar David VillarrealYu Chang WangJiannis RagoussisSerge RivestDavid GosselinStéphane RichardPublished in: Life science alliance (2022)
Remyelination failure in multiple sclerosis leads to progressive demyelination and inflammation, resulting in neurodegeneration and clinical decline. Microglia are innate immune cells that can acquire a regenerative phenotype to promote remyelination, yet little is known about the regulators controlling the regenerative microglia activation. Herein, using a cuprizone (CPZ)-diet induced de- and remyelination mice model, we identify PRMT1 as a driver for MHC-associated microglia population required for remyelination in the central nervous system. The loss of PRMT1, but not PRMT5, in microglia resulted in impairment of the remyelination with a reduction of oligoprogenitor cell number and prolonged microgliosis and astrogliosis. Using single-cell RNA sequencing, we found eight distinct microglial clusters during the CPZ diet, and PRMT1 depleted microglia hindered the formation of the MHC-associated cluster, expressing MHCII and CD11c. Mechanistically, PRMT1-KO microglia displayed reduced the H3K27ac peaks at the promoter regions of the MHC- and IFN-associated genes and further suppressed gene expression during CPZ diet. Overall, our findings demonstrate that PRMT1 is a critical regulator of the MHC- and IFN-associated microglia, necessary for central nervous system remyelination.
Keyphrases
- inflammatory response
- neuropathic pain
- single cell
- multiple sclerosis
- gene expression
- immune response
- stem cells
- cell therapy
- mesenchymal stem cells
- dna methylation
- lipopolysaccharide induced
- transcription factor
- physical activity
- spinal cord
- rna seq
- lps induced
- oxidative stress
- cerebrospinal fluid
- type diabetes
- white matter
- genome wide
- metabolic syndrome